Latest Breaking News On - Phase 2a mylox 1 trial nct04679870 - Page 1 : comparemela.com

The potential first-in-class, oral, lysyl oxidase-like 2 inhibitor GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.

City ofUnited kingdomClaire harrisonHanst schambyeDynamic international prognostic scoringGalecto incSafety review committeeTotal symptom scorePhase 2a mylox 1 trial nct04679870Lysyl oxidase like 2 inhibitor